FDA gives Epizyme a green light on trial recruitment, but tazemetostat isn’t completely out of the woods yet

Epizyme is reporting that the FDA has lifted the partial hold it imposed on their clinical trial work for the lead drug tazemetostat, but it has some work yet to do before it gets all the studies back on track.